121 related articles for article (PubMed ID: 35575420)
1. Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form.
Sahasrabudhe V; Matschke K; Shi H; Hickman A; Kong A; Rodríguez Spong B; Nickerson B; Arora KK
Int J Clin Pharmacol Ther; 2022 Jul; 60(7):317-326. PubMed ID: 35575420
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Dawra VK; Liang Y; Wei H; Pelletier K; Shi H; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):50-61. PubMed ID: 31207178
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Fediuk DJ; Matschke K; Liang Y; Pelletier KB; Wei H; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):884-894. PubMed ID: 31219248
[TBL] [Abstract][Full Text] [Related]
5. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
[TBL] [Abstract][Full Text] [Related]
6. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
[TBL] [Abstract][Full Text] [Related]
7. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
9. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
Li Y; Nucci G; Yamamoto Y; Fediuk DJ; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):765-776. PubMed ID: 33434408
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
[TBL] [Abstract][Full Text] [Related]
14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Dawra VK; Cutler DL; Zhou S; Krishna R; Shi H; Liang Y; Alvey C; Hickman A; Saur D; Terra SG; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):314-325. PubMed ID: 29786959
[TBL] [Abstract][Full Text] [Related]
16. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
17. Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
Sahasrabudhe V; Fediuk DJ; Matschke K; Shi H; Liang Y; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Dawra VK
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):619-627. PubMed ID: 30427588
[TBL] [Abstract][Full Text] [Related]
18. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.
Fediuk DJ; Sahasrabudhe V; Dawra VK; Zhou S; Sweeney K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1297-1306. PubMed ID: 34213819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]